ANAGRELIDE

Other

Brand names: Anagrelide

Oral

Mechanism of Action

12.1 Mechanism of Action The precise mechanism by which anagrelide reduces blood platelet count is unknown. In cell culture studies, anagrelide suppressed expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.

Indications

1 INDICATIONS & USAGE Anagrelide capsules are indicated for the treatment of patients with thrombocythemia

secondary to myeloproliferative neoplasms

to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. (1)

Contraindications

• 4 CONTRAINDICATIONS None. None (4)

FDA Warnings

5 WARNINGS AND PRECAUTIONS Cardiovascular Toxicity: QT prolongation and ventricular tachycardia have been reported with anagrelide
2) Bleeding Risk: Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding
Do not use anagrelide in patients with known risk factors for QT interval prolongation, such as congenital long QT syndrome, a known history of acquired QTc prolongation, medicinal products that can prolong QTc interval and hypokalemia [see Drug Interactions (7
Hepatic impairment increases anagrelide exposure and could increase the risk of QTc prolongation

Known Side Effects

9 documented side effects by frequency

Fatigue

1-10%

Headache

1-10%

Diarrhea

1-10%

Dizziness

1-10%

Drug Not Working

1-10%

Shortness of Breath

1-10%

Nausea

0.1-1%

Weakness

0.1-1%

Falls

0.1-1%

Community Discussions

No community discussions found for ANAGRELIDE yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral